Teva Posts Strong Q1 2026 Results, Eyes Share Buybacks

Teva Pharmaceutical ( (TEVA) ) has issued an update.

Teva Pharmaceutical Industries Ltd. is a global pharmaceutical company focused on both innovative and generic medicines, with a growing portfolio in neuroscience, migraine, psychiatric disorders and biosimilars. The company is reshaping its portfolio mix toward higher-margin branded and biosimilar products while leveraging its traditional generics footprint to support its Pivot to Growth strategy.

Teva reported strong first-quarter 2026 results on April 29, 2026, with revenues of about $4.0 billion, higher gross margins, and robust growth from key innovative brands AUSTEDO, AJOVY and UZEDY, which collectively grew 41% year over year in local currency. While U.S. generics revenues fell, mainly due to intensified competition for lenalidomide, biosimilars such as PONLIMSI and recent launches helped offset pressure, and an agreement to acquire Emalex Biosciences is set to add an NDA-ready Tourette syndrome therapy to the neuroscience pipeline.

Teva maintained its 2026 business outlook with revenues projected at $16.4–$16.8 billion, adjusting profitability guidance to reflect Emalex-related IPR&D and operating costs, and reaffirmed ambitions for a 30% non-GAAP operating margin and about $700 million in net savings by 2027. The board also instructed management to plan a potential share repurchase program, signaling confidence in the company’s financial trajectory as it advances late-stage assets including duvakitug for inflammatory bowel disease and an olanzapine long-acting injectable for schizophrenia.

The most recent analyst rating on (TEVA) stock is a Buy with a $41.00 price target. To see the full list of analyst forecasts on Teva Pharmaceutical stock, see the TEVA Stock Forecast page.

Spark’s Take on TEVA Stock

According to Spark, TipRanks’ AI Analyst, TEVA is a Neutral.

The score is driven primarily by improving fundamentals (return to profitability and solid free cash flow) but constrained by elevated leverage and historical volatility. Technicals are supportive with strong uptrend momentum, while valuation is a headwind at a ~27 P/E and no dividend yield. Earnings-call guidance is constructive on margins, growth brands, and deleveraging, but near-term revenue and quarterly volatility risks cap the upside.

To see Spark’s full report on TEVA stock, click here.

More about Teva Pharmaceutical

Teva Pharmaceutical Industries Ltd. is a global pharmaceutical company focused on both innovative and generic medicines, with a growing portfolio in neuroscience, migraine, psychiatric disorders and biosimilars. The company is reshaping its portfolio mix toward higher-margin branded and biosimilar products while leveraging its traditional generics footprint to support its Pivot to Growth strategy.

Teva reported strong first-quarter 2026 results on April 29, 2026, with revenues of about $4.0 billion, higher gross margins, and robust growth from key innovative brands AUSTEDO, AJOVY and UZEDY, which collectively grew 41% year over year in local currency. While U.S. generics revenues fell, mainly due to intensified competition for lenalidomide, biosimilars such as PONLIMSI and recent launches helped offset pressure, and an agreement to acquire Emalex Biosciences is set to add an NDA-ready Tourette syndrome therapy to the neuroscience pipeline.

Teva maintained its 2026 business outlook with revenues projected at $16.4–$16.8 billion, adjusting profitability guidance to reflect Emalex-related IPR&D and operating costs, and reaffirmed ambitions for a 30% non-GAAP operating margin and about $700 million in net savings by 2027. The board also instructed management to plan a potential share repurchase program, signaling confidence in the company’s financial trajectory as it advances late-stage assets including duvakitug for inflammatory bowel disease and an olanzapine long-acting injectable for schizophrenia.

Average Trading Volume: 7,190,123

Technical Sentiment Signal: Buy

Current Market Cap: $37B

Find detailed analytics on TEVA stock on TipRanks’ Stock Analysis page.